Full-Time

Principal Data Engineer

Posted on 5/16/2026

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

No salary listed

Philadelphia, PA, USA

Remote

Category
Data & Analytics (2)
,
Required Skills
Kubernetes
MLOps
Redshift
Python
NoSQL
Data Science
R
SQL
RDBMS
ETL
Docker
AWS
DevOps
Requirements
  • Strong knowledge of data engineering tools such as Python, R and SQL for data processing.
  • Strong proficiency with AWS services particularly S3, Redshift, FSx, Glue, Lambda.
  • Strong proficiency with relational databases.
  • Strong background in data modeling and database design.
  • Familiarity with unstructured database technologies (e.g. NoSQL) and other database types (e.g. Graph).
  • Familiarity with Containerization such as Docker and EKS/Kubernetes.
  • Familiarity with one or more RnD research process and associated regulatory requirements.
  • Exposure to healthcare data standards (CDISC, HL7, FHIR, SNOMED CT, OMOP, DICOM).
  • Exposure to big data technologies and handling.
  • Knowledge of machine learning operations (MLOps) and model deployment.
  • Strong problem-solving and analytical abilities.
  • Excellent communication skills for collaborating with stakeholders.
  • Experience working in an Agile development environment.
  • Bachelor’s Degree in Computer Science, Statistics, Mathematics, Life Sciences, or other relevant scientific fields; Master’s Degree preferred
Responsibilities
  • Support the design, development and maintenance of data pipelines for processing Research and Development data from diverse sources (Clinical Trials, Medical Devices, Pre-Clinical, Omics, Real World Data) utilizing the AWS technology platform.
  • Create and optimize ETL/ELT processes for structured and unstructured data using Python, R, SQL, AWS services and other tools.
  • Build and maintain data repositories using AWS S3 and FSx technologies. Establish data warehousing solutions using Amazon Redshift.
  • Build and maintain standard data models.
  • Develop data quality frameworks, validation processes and KPIs to ensure accuracy and consistency of data pipelines.
  • Implement data versioning and lineage tracking to support data traceability, regulatory compliance and audit requirements.
  • Create and maintain documentation for data processes, architectures, and workflows.
  • Implement modern software development best practices (e.g. Code Versioning, DevOps, CD/CI).
  • Support collaboration with RnD Researchers, Data scientists and Stakeholders to understand data requirements and deliver appropriate solutions in a global working model.
  • Maintain compliance with data privacy regulations such as HIPAA, GDPR
  • May be required to develop, deliver or support data literacy training across R&D.
Desired Qualifications
  • Master’s Degree preferred

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • 2025 revenue reached $4.3 billion, up 5%, with $1.4 billion operating cash flow.
  • Zanidatamab priority review and RTOR filing target first-line HER2-positive gastroesophageal adenocarcinoma.
  • Chimerix's dordaviprone expands Jazz into rare neuro-oncology after April 2025 acquisition.

What critics are saying

  • Xywav growth moderates as Xyrem declines, weakening the sleep franchise's cash engine.
  • Epidiolex concentration creates payer and reimbursement exposure across roughly a quarter of revenue.
  • M&A discipline remains unproven; another expensive acquisition could destroy shareholder value.

What makes Jazz Pharmaceuticals unique

  • Jazz balances neuroscience and oncology with blockbuster rare-disease franchises.
  • Xywav replaced declining Xyrem, sustaining sleep-disorder leadership and growth.
  • Epidiolex and Zepzelca diversify revenue beyond a single therapeutic category.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Jazz Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.